Qiagen NV (QGEN) Stock Analysis
Verdict: WATCH (do not buy)
Solid 20.7% operating margins and dPCR expansion support stable cash flow, but sluggish 4.8% revenue growth limits upside near $42.51 consensus.
Investment score: 54/100
Analysis as of
Is Qiagen NV stock worth reviewing? AI model thesis
The model views QGEN as a stable defensive holding with high gross margins (62.6%) and healthy FCF ($453.3M), but muted revenue growth (4.79%) and proximity to analyst price targets ($42.51) justify a Hold rating.
7-factor investment score
- Valuation: 52/100 (weight 20%)
- Financial Health: 78/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 52/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Qiagen NV opportunities and risks
What speaks for QGEN
- Expansion in Digital PCR (QIAcuity) and Next-Gen Sequencing Panels
What speaks against QGEN
- Biopharma and Academic Research Spending Slowdown
Frequently asked questions about Qiagen NV (QGEN)
Is QGEN stock a good investment?
The cached TradeMates AI model rates Qiagen NV as WATCH (do not buy) with an investment score of 54/100. The model views QGEN as a stable defensive holding with high gross margins (62.6%) and healthy FCF ($453.3M), but muted revenue growth (4.79%) and proximity to analyst price targets ($42.51) justify a Hold rating. This is algorithmic model output, not personal investment advice.
Is QGEN stock a buy?
The TradeMates model verdict for QGEN is WATCH (do not buy) with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.